(Sunday, 7/12/2020) [Eastern Time (GMT-4)]
Room: AAPM ePoster Library
Purpose: compare 200 endometrial cancer patients treated in our center with cylindrical applicators and Axxent (Xoft Inc.) electronic brachytherapy and equivalent planning made for Ir-192 source and Co-60. In addition, evaluate cases of acute toxicity
Methods: patients previously treated with Axxent (50 kV source) were replanned with Ir-192 and Co-60 source. The calculation for three types of source were performed on BrachyVision (Varian Inc.) treatment planning system.
The prescription was 7 Gy per fraction. Planning parameters of a planning target volume (PTV) countoured from the cylinder surface to 5 mm along the active length were evaluated. V150 and V200 data for PTV and D2cc, V50% and V35% for organs at risk (OAR) were evaluated, the percentage volume receiving 35% and 50% of the prescription dose, respectively, and D2cc, highest dose to a 2 cc volume of an OAR. Results for bladder, rectum and sigmoid are showed.
Results: may observe a reduction in dose at V35% and V50% in all OAR and also a reduction in D2cc occurs.(Table 1). PTV parameters increase in the case of Axxent ,as reported previously, but only 1.5% of cases of vaginal mucositis with grade 3 or higher were reported in our center.
Conclusion: are very optimistic about the adequacy of Xoft equipment for treatment of endometrial cancer with a clear reduction of the physical dose in organs at risk and no development of acute mucositis except one patient despite the considerable increase V150 in the treatment volume.Likewise, patients do not present acute toxicities in the bladder or rectum.
Keywords
Taxonomy
TH- Brachytherapy: GYN Intracavity Brachytherapy
Contact Email
